Advances in molecular profiling and sensor technologies are expanding the scope of personalized medicine beyond genotypes, providing new opportunities for developing richer and more dynamic multiscale models of individual health 1,2 . Recent studies demonstrate the value of scoring high-dimensional microbiome 3 , immune 4 , and metabolic 5 traits from individuals to inform personalized medicine. Efforts to integrate multiple dimensions of clinical and molecular data towards predictive multi-scale models of individual health and wellness are already underway 6-8 . Improved methods for mining and discovery of clinical phenotypes from electronic medical records 9 and technological developments in wearable sensor technologies present new opportunities for mapping and exploring the critical yet poorly characterized "phenome" and "envirome" dimensions of personalized medicine 10, 11 . There are ambitious new projects underway to collect multi-scale molecular, sensor, clinical, behavioral, and environmental data streams from large population cohorts longitudinally to enable more comprehensive and dynamic models of individual biology and personalized health 12 . Personalized medicine stands to benefit from inclusion of rich new sources and dimensions of data. However, realizing these improvements in care relies upon novel informatics methodologies, tools, and systems to make full use of these data to advance both the science and translational applications of personalized medicine. 
Genotyping and large-scale molecular phenotyping are already available for large patient cohorts and may soon become available for many patients. Exome or complete genome sequences are increasingly being collected, and in some cases are now covered by insurance. Prenatal diagnosis has been improved by genotyping fetal DNA circulating in mother's blood tissue. Robust statistical and computational methods for analyzing these data will be critical to realizing the promise of personalized medicine. The challenges span from accurate low-level analyses of high throughput datasets to high-level synthesis of mechanisms of action, and identification of causal links between different abstract layers of molecular information, before, finally, incorporating them into health-care such as diagnostics. Important analysis problems include accurate phenotypic characterization, identifying and correcting for latent structure, dealing with missing data, deciding at what level to test (e.g., within genomes, whether to use single base pair values, sets of polymorphisms, exonic regions, etc.), data heterogeneity, the problem of multiple testing, integrating various modalities, deducing functional consequences in silico, addressing data quality, and making sense of new data types as they become available.
The path from genotype to disease state goes through intermediate phenotypes. To modulate the disease risk or trait, one of the molecular intermediates must be changed in a controlled way using small molecules or changes in environment. Finding the right intermediate molecule to target for these interventions remains a key challenge. A first level of understanding should come from genetic mapping studies -that is, to determine to which extent do the loci responsible for heritable disease risk affect intermediate traits. Much progress has been made on this front over the last years, especially for genetic control of RNA levels 13,14 -so-called "eQTL" analysis, but also for protein, metabolite and epigenetic modification abundances [15] [16] [17] [18] , with much remaining to be done. The next task is distinguishing the actual drivers of ailment from traits that do respond to genotype, but do not cause disease. Causal models, such as those based on Mendelian randomization and mediation analysis, will play a crucial role in separating out the molecular causes of disease from the high-dimensional state of the organism 19, 20 .
Medicine is gradually moving away from the traditional model of reactive sick-care towards wellness and all-time learning healthcare systems that aim to prevent individuals from perturbing their individual biology towards states of disease 1, 2 . Personalized medicine aims to soon allow dynamic, quantitative representation of an individual patient's heath "GPS coordinates" estimated from multiple modalities of personal health data 1 . Still, much work is required in all areas, from basic discovery of molecular mechanisms of disease pathology, to statistical methods of causality and publicly available computational infrastructure to deliver on the promise of genetic and other personalized information in the clinic and beyond.
Session contributions
Dr. Nathan Price gives the invited talk. Dr. Price, along with colleagues at the Institute for Systems Biology, is spearheading the innovative Wellness 1K program that aims to take personalized medicine from "sick care" to maintenance of wellness by way of democratized healthcare 2 .
The electronic medical record (EMR) captures clinical phenotype information and is being used increasingly as an important source of research data for precision medicine discovery. In our session, Glicksberg et al. discuss a novel integrative method combing genetic and EMR data for data-driven discovery of disease relationships. Efficient methods for inferring causal relationships across multiple scales of molecular traits are critical for modeling the complexity of biological systems. In our session, Chang et al. describe a novel method using Bayesian belief propagation for inferring the responses of perturbation events on molecular traits given a hypothesized graph structure. The method is not constrained by the conditional dependency arguments that limit the ability of statistical causal inference methods to resolve causal relationships within sets of graphical models that are Markov equivalent. The authors infer causal relationships from synthetic microarray and RNA sequencing data, and also apply their method to infer causality in real metabolic network with v-structure and feedback loop. Their approach is found to recapitulate the causal structure and recover the feedback loop given only steady-state data.
Accurate detection and modeling of tumor heterogeneity is a central challenge in understanding tumorigeneis and individual patient tumor characteristics. In our session, Sengupta et al. present a novel approach for modeling tumor heterogeneity (TH) using next-generation sequencing (NGS) data. The authors take a Bayesian approach that extends the Indian buffet process (IBP) to define a class of nonparametric models. Instead of partitioning somatic mutations into non-overlapping clusters with similar cellular prevalences, the authors do not assume somatic mutations with similar cellular prevalence Pacific Symposium on Biocomputing 2015 must be from the same subclone and allow overlapping mutations shared across subclones. The authors argue that this representation is closer to the underlying theory of phylogenetic clonal expansion, where somatic mutations occurred in parent subclones should be shared across the parent and child subclones. Their method yields posterior probabilities of the number, genotypes, and proportions of subclones in a tumor sample, thereby providing point estimates as well as variabilities of the estimates for each subclone. The method is implemented in a software package called BayClone that is made available for download.
Technological advances and increased public availability of data offer new opportunities to gain insights into the complexity of the eukaryotic transcriptome. Alternative cleavage of 3' UTRs has numerous functional consequences pertaining to the stability, transport, and translocation of transcripts. 3' UTR cleavages site analysis is also important clinically, particularly in cancer, where proto-oncogene can be activated by mRNA isoforms having shorter cleaved 3' UTRs. Thus both biological investigations and clinical applications benefit from more accurate methods for cleavage site analysis from transcriptional profiling data. In our session, Birol et al. describe KLEAT, a novel analysis tool that uses de novo assembly of RNA-sequencing data to search for and prioritize cleavage sites in poly(A) tails. The authors apply KLEAT to RNA-sequence data from ENCODE cell lines for which RNA-PET libraries are also available to compare predicted and actual 3' poly(A) signatures. The authors find that KLEAT exhibits > 90% positive predictive value when there are at least three RNA-sequencing reads supporting a poly(A) using the validation criteria of a minimum of three RNA-PET reads mapping within 100 nucleotides. The KLEAT software may accelerate biological and clinical applications of 3' UTR cleavage site analysis by enabling accurate analysis from more standard RNA-sequencing data and obviating the need for specialized wet lab techniques or sequencing libraries.
Though thousands of genes are implicated as underlying factors of disease it remains challenging to identify highest-value targets for novel drug development. In our session, Gao et al. address the question whether genes affected by strong genetic or environmental effects present better proxy therapeutic drug targets. To address this question, the authors propose a modeling approach that recovers both regulatory networks and estimates of environmental and genetic effects on gene expression. They apply their method to a gene expression data measured from blood samples from monozygotic and dizygotic twins and use the Connectivity Map database to assess whether genetic or environmental effects are more informative of gene's competency as a proxy target. The study findings suggest that a gene with strong genetic effects is more likely to act as a proxy target than a gene with strong environmental effects. This raises the intriguing hypothesis that diversity of a gene's expression across a genetically diverse population that makes it a suitable proxy rather than its sensitivity to environmental effects.
Finally, Fan-Minogue et al. evaluate the effectiveness of the differential expression (DE), diseaseassociated single nucleotide polymorphisms (SNPs) and combination of the two in recovering known therapeutic targets across 56 human diseases. They find that the performance of each feature varies across diseases and generally the features have more recovery power than predictive power. The systematic study results offer compelling evidence that the combination of the two features has more predictive power than each feature alone.
